This medical device innovator, focused on vascular surgery solutions, reported a notable insider sale amid steady financial performance.

Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinica ...

Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase ...

Using electrosurgical disruption of the chronic dissection septum to expand true lumen channel and improve stent graft ...

Gurgaon undergoes complex vascular surgery to save leg; city reports 10,067 dog bite cases in 2025, raising concern.

Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - ...

The peripheral vascular device market will rise from $10.4B in 2025 to $14.8B by 2032, driven by drug‑coated balloons, ...

More than 10,000 Americans are waiting for a liver transplant. Many more never make the list, because they are too sick to handle a major surgery. That gap is why an idea that sounds a little strange ...

VentureMed Group, Inc., an innovative medical device company specializing in vessel preparation and access management for AV fistulas and grafts and peripheral vascular disease, today announced it is ...